Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.50 |
| ▸ | MC4R | P32245 | 2/20 | 0.50 |
| ▸ | MC5R | P33032 | 2/20 | 0.50 |
| ▸ | MC3R | P41968 | 1/20 | 0.50 |
| ▸ | MARS1 | P56192 | 5/20 | 0.44 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CASP2 | P42575 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | F13A1 | P00488 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | CA4 | P22748 | 2/20 | 0.41 |
| ▸ | CA6 | P23280 | 2/20 | 0.41 |
| ▸ | CA5A | P35218 | 2/20 | 0.41 |
| ▸ | THPO | P40225 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL625484 | 0.96 | CHRM2 (0.51) | CHRM2MC4RMC5RMC3RMARS1 | |
| SCHEMBL625986 | 0.92 | CHRM2 (0.56) | CHRM2MC4RMC5RMC3RMARS1 | |
| SCHEMBL626270 | 0.92 | CHRM2 (0.56) | CHRM2MC4RMC5RMC3RMARS1 | |
| SCHEMBL6875413 | 0.92 | CHRM2 (0.56) | CHRM2MC4RMC5RMC3RMARS1 | |
| SCHEMBL626377 | 0.92 | CHRM2 (0.56) | CHRM2MC4RMC5RMC3RMARS1 | |
| SCHEMBL625735 | 0.92 | CHRM2 (0.48) | CHRM2MC4RMC5RMC3RMARS1 | |
| SCHEMBL16151783 | 0.85 | MC4R (0.58) | CHRM2MC4RMC5RMC3RKAT2B | |
| Hydrochloric Acid SCHEMBL29778318 | 0.83 | MC4R (0.56) | CHRM2MC4RMC5RMC3RKAT2B | |
| SCHEMBL10909031 | 0.82 | CHRM2 (0.77) | CHRM2MC4RMC5RMC3RCYP1A2 | |
| SCHEMBL16435203 | 0.81 | MC4R (0.55) | MC4RMC5RMC3RSMN1; SMN2CASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9192569-B2 | Formulations for infusion of type B lantibiotics | NOVACTA BIOSYSTEMS LIMITED (GB) | 2015-11-24 | — | — | US | disclosed |
| US-9006392-B2 | Actagardine derivatives, and pharmaceutical use thereof | NOVACTA BIOSYSTEMS LIMITED (GB) | 2015-04-14 | — | — | US | disclosed |
| US-8729031-B2 | Compounds | NOVACTA BIOSYSTEMS LIMITED (GB) | 2014-05-20 | — | — | US | disclosed |
| EP-2603204-A2 | FORMULATIONS FOR INFUSION OF TYPE B LANTIBIOTICS | Novacta Biosystems Limited (GB) | 2013-06-19 | — | — | EP | disclosed |
| US-20130137630-A1 | FORMULATIONS FOR INFUSION OF TYPE B LANTIBIOTICS | NOVACTA BIOSYSTEMS LIMITED (GB) | 2013-05-30 | — | — | US | disclosed |
| US-20120302728-A1 | Actagardine Derivatives, and Pharmaceutical Use Thereof | NOVACTA BIOSYSTEMS LIMITED (GB) | 2012-11-29 | — | — | US | disclosed |
| WO-2012020219-A2 | FORMULATIONS FOR INFUSION OF TYPE B LANTIBIOTICS | NOVACTA BIOSYSTEMS LIMITED (GB) | 2012-02-16 | — | — | WO | disclosed |
| EP-2393829-A1 | ACTAGARDINE DERIVATIVES | Novacta Biosystems Limited (GB) | 2011-12-14 | — | — | EP | disclosed |
| US-20110294723-A1 | Compounds | NOVACTA BIOSYSTEMS LIMITED (GB) | 2011-12-01 | — | — | US | disclosed |
| WO-2011095769-A1 | ACTAGARDINE DERIVATIVES, AND PHARMACEUTICAL USE THEREOF | NOVACTA BIOSYSTEMS LIMITED (GB) | 2011-08-11 | — | — | WO | disclosed |
| WO-2010089544-A1 | ACTAGARDINE DERIVATIVES | NOVACTA BIOSYSTEMS LIMITED (GB) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137630-A1 | FORMULATIONS FOR INFUSION OF TYPE B LANTIBIOTICS | SLC5A2, SLC5A11, SPTSSB | CHRM2 4065/4885MC4R 1975/4885MC5R 3239/4885 |
| US-20120302728-A1 | Actagardine Derivatives, and Pharmaceutical Use Thereof | GALR2, GALR1, GALR3 | CHRM2 463/4885MC4R 635/4885MC5R 405/4885 |
| US-20110294723-A1 | Compounds | SLC11A2, SDHA, SDHB | CHRM2 4696/4885MC4R 2593/4885MC5R 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.